Adial Pharmaceuticals Implements Reverse Stock Split to Regain Compliance

Adial Pharmaceuticals ( (ADIL) ) has shared an announcement.

On August 1, 2025, shareholders of Adial Pharmaceuticals approved a reverse stock split of the company’s common stock, and the board later set the final ratio at 1-for-25, with the split becoming legally effective at 11:59 p.m. Eastern Time on February 5, 2026; trading on a split-adjusted basis on the Nasdaq Capital Market under the existing ticker “ADIL” commenced on February 6, 2026. The move reduced Adial’s outstanding common shares from about 27.8 million to approximately 1.1 million without changing the total number of authorized shares, preserved proportional ownership aside from the cash-out of fractional shares, and adjusted outstanding equity awards and warrants, as the company sought to lift its per-share trading price to regain compliance with Nasdaq’s minimum $1.00 bid requirement and potentially broaden its appeal among institutional and retail investors.

The most recent analyst rating on (ADIL) stock is a Hold with a $0.20 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.

Spark’s Take on ADIL Stock

According to Spark, TipRanks’ AI Analyst, ADIL is a Neutral.

The score is held down primarily by weak fundamentals (no revenue, ongoing losses, and persistent cash burn) and a bearish technical backdrop (below key moving averages with negative MACD). A modest positive offset comes from a low-leverage balance sheet and the recent $2.86M financing that supports near-term liquidity.

To see Spark’s full report on ADIL stock, click here.

More about Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for addictions and related disorders. Its lead investigational drug, AD04, is a genetically targeted serotonin-3 receptor antagonist for treating Alcohol Use Disorder in heavy-drinking patients with specific genotypes, with additional potential applications in other addictive conditions such as opioid use disorder, gambling and obesity.

Average Trading Volume: 337,110

Technical Sentiment Signal: Sell

Current Market Cap: $5.96M

For a thorough assessment of ADIL stock, go to TipRanks’ Stock Analysis page.